OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist
Yun Kyung Cho, Yoo La Lee, Chang Hee Jung
Journal of Lipid and Atherosclerosis (2023) Vol. 12, Iss. 3, pp. 213-213
Open Access | Times Cited: 24
Yun Kyung Cho, Yoo La Lee, Chang Hee Jung
Journal of Lipid and Atherosclerosis (2023) Vol. 12, Iss. 3, pp. 213-213
Open Access | Times Cited: 24
Showing 24 citing articles:
Psychotropic Drug–Related Weight Gain and Its Treatment
Roger S. McIntyre, Angela T.H. Kwan, Joshua D. Rosenblat, et al.
American Journal of Psychiatry (2024) Vol. 181, Iss. 1, pp. 26-38
Closed Access | Times Cited: 43
Roger S. McIntyre, Angela T.H. Kwan, Joshua D. Rosenblat, et al.
American Journal of Psychiatry (2024) Vol. 181, Iss. 1, pp. 26-38
Closed Access | Times Cited: 43
Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis
Maria‐Ioanna Stefanou, Aikaterini Theodorou, Konark Malhotra, et al.
European Stroke Journal (2024) Vol. 9, Iss. 3, pp. 530-539
Open Access | Times Cited: 20
Maria‐Ioanna Stefanou, Aikaterini Theodorou, Konark Malhotra, et al.
European Stroke Journal (2024) Vol. 9, Iss. 3, pp. 530-539
Open Access | Times Cited: 20
Advancements in risk stratification and management strategies in primary cardiovascular prevention
Fotios Barkas, Yusuf Ziya Şener, Pelin Golforoush, et al.
Atherosclerosis (2024) Vol. 395, pp. 117579-117579
Closed Access | Times Cited: 14
Fotios Barkas, Yusuf Ziya Şener, Pelin Golforoush, et al.
Atherosclerosis (2024) Vol. 395, pp. 117579-117579
Closed Access | Times Cited: 14
Evidence that tirzepatide protects against diabetes-related cardiac damages
Fatemeh Taktaz, Lucia Scisciola, Rosaria Anna Fontanella, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 13
Fatemeh Taktaz, Lucia Scisciola, Rosaria Anna Fontanella, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 13
Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 13
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 13
New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review
Jorge Jalil, Luigi Gabrielli, María Paz Ocaranza, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4407-4407
Open Access | Times Cited: 8
Jorge Jalil, Luigi Gabrielli, María Paz Ocaranza, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4407-4407
Open Access | Times Cited: 8
Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study
Matthew Anson, Alex E. Henney, Nicholas Broadwell, et al.
EClinicalMedicine (2024) Vol. 75, pp. 102777-102777
Open Access | Times Cited: 7
Matthew Anson, Alex E. Henney, Nicholas Broadwell, et al.
EClinicalMedicine (2024) Vol. 75, pp. 102777-102777
Open Access | Times Cited: 7
Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging
Ibrahim Alradwan, Nojoud AL Fayez, Mohammad N. Alomary, et al.
Pharmaceutics (2024) Vol. 16, Iss. 8, pp. 1037-1037
Open Access | Times Cited: 6
Ibrahim Alradwan, Nojoud AL Fayez, Mohammad N. Alomary, et al.
Pharmaceutics (2024) Vol. 16, Iss. 8, pp. 1037-1037
Open Access | Times Cited: 6
The current landscape for diabetes treatment: Preventing diabetes-associated CV risk
Angela Dardano, Cristina Bianchi, Monia Garofolo, et al.
Atherosclerosis (2024) Vol. 394, pp. 117560-117560
Closed Access | Times Cited: 5
Angela Dardano, Cristina Bianchi, Monia Garofolo, et al.
Atherosclerosis (2024) Vol. 394, pp. 117560-117560
Closed Access | Times Cited: 5
Clinical Update in Heart Failure with Preserved Ejection Fraction
Chayakrit Krittanawong, William Britt, Affan Rizwan, et al.
Current Heart Failure Reports (2024) Vol. 21, Iss. 5, pp. 461-484
Closed Access | Times Cited: 5
Chayakrit Krittanawong, William Britt, Affan Rizwan, et al.
Current Heart Failure Reports (2024) Vol. 21, Iss. 5, pp. 461-484
Closed Access | Times Cited: 5
Weight Loss Therapies and Hypertension Benefits
Vasiliki Katsi, Eleni Manta, Christos Fragoulis, et al.
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2293-2293
Open Access | Times Cited: 5
Vasiliki Katsi, Eleni Manta, Christos Fragoulis, et al.
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2293-2293
Open Access | Times Cited: 5
Prevalence, Incidence, and Metabolic Characteristics of Young Adults with Type 2 Diabetes Mellitus in South Korea (2010–2020)
Ji Yoon Kim, Jiyoon Lee, Joon Ho Moon, et al.
Diabetes & Metabolism Journal (2025) Vol. 49, Iss. 2, pp. 172-182
Open Access
Ji Yoon Kim, Jiyoon Lee, Joon Ho Moon, et al.
Diabetes & Metabolism Journal (2025) Vol. 49, Iss. 2, pp. 172-182
Open Access
Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia
Brian Tomlinson, Paul Chan
Expert Opinion on Pharmacotherapy (2025), pp. 1-11
Closed Access
Brian Tomlinson, Paul Chan
Expert Opinion on Pharmacotherapy (2025), pp. 1-11
Closed Access
Journal of Lipid and Atherosclerosis Update 2025
Ji Hye Heo, In‐Kyung Jeong
Journal of Lipid and Atherosclerosis (2025) Vol. 14, Iss. 1, pp. 3-3
Open Access
Ji Hye Heo, In‐Kyung Jeong
Journal of Lipid and Atherosclerosis (2025) Vol. 14, Iss. 1, pp. 3-3
Open Access
The widespread adoption of glucagon-like peptide-1 receptor agonists in the management of obesity and its implications for the anaesthesiologist and intensivist: A narrative review
Travis Browning, Abigail E Coy, Vishal Sehgal, et al.
(2025) Vol. 1, pp. 9-18
Closed Access
Travis Browning, Abigail E Coy, Vishal Sehgal, et al.
(2025) Vol. 1, pp. 9-18
Closed Access
Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients
Jheng‐Yan Wu, Wu-Hao Tu, Tsung Yu, et al.
Diabetes Research and Clinical Practice (2025) Vol. 222, pp. 112083-112083
Closed Access
Jheng‐Yan Wu, Wu-Hao Tu, Tsung Yu, et al.
Diabetes Research and Clinical Practice (2025) Vol. 222, pp. 112083-112083
Closed Access
Exploring the Effects of Tirzepatide on Obstructive Sleep Apnea: A Literature Review
Jimmy Wen, Denise Nadora, Alina Truong, et al.
Cureus (2025)
Open Access
Jimmy Wen, Denise Nadora, Alina Truong, et al.
Cureus (2025)
Open Access
Insulin requirements after switching from GLP ‐1 receptor agonist to dual GIP /GLP ‐1 receptor agonist in patients with type 2 diabetes mellitus
Alexa M. Lahey, Karolyn S. Duprey, Richard J. Montague, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2025)
Closed Access
Alexa M. Lahey, Karolyn S. Duprey, Richard J. Montague, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2025)
Closed Access
Tirzepatid und Blutdruck
Markus van der Giet
CardioVasc (2025) Vol. 25, Iss. 2, pp. 30-31
Closed Access
Markus van der Giet
CardioVasc (2025) Vol. 25, Iss. 2, pp. 30-31
Closed Access
Tirzepatide’s innovative applications in the management of type 2 diabetes and its future prospects in cardiovascular health
Jingqi Yang, Yuncheng Gu, Huaigang Chen, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Jingqi Yang, Yuncheng Gu, Huaigang Chen, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes: an update
Brian Tomlinson, Paul Chan
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 4, pp. 175-179
Closed Access | Times Cited: 1
Brian Tomlinson, Paul Chan
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 4, pp. 175-179
Closed Access | Times Cited: 1
Options for patients with out-of-control blood pressure: after all avenues have been exhausted
Weiwei Zeng, Brian Tomlinson
Expert Review of Cardiovascular Therapy (2024), pp. 1-12
Closed Access | Times Cited: 1
Weiwei Zeng, Brian Tomlinson
Expert Review of Cardiovascular Therapy (2024), pp. 1-12
Closed Access | Times Cited: 1
Tirzepatide - A Revolution in Obesity Treatment?
Aleksandra Jaroń, Katarzyna Jastrzębska, Klara Wojciechowska, et al.
Quality in Sport (2024) Vol. 17, pp. 53102-53102
Open Access
Aleksandra Jaroń, Katarzyna Jastrzębska, Klara Wojciechowska, et al.
Quality in Sport (2024) Vol. 17, pp. 53102-53102
Open Access
Tirzepatide: a dual-action solution for obstructive sleep apnea and obesity
Zain Afridi, Kanza Farhan, Fnu Fahad, et al.
Annals of Medicine and Surgery (2024) Vol. 87, Iss. 2, pp. 436-437
Open Access
Zain Afridi, Kanza Farhan, Fnu Fahad, et al.
Annals of Medicine and Surgery (2024) Vol. 87, Iss. 2, pp. 436-437
Open Access
